Ligand validation:6JR2

36J: (3S,7R,11E)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10-octahydro-1H-2-benzoxacyclotetradecin-1-one

36J is a Ligand Of Interest in 6JR2 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6JR2_36J_B_301	77%	58%	0.093	0.932	0.92	0.69	1	-	0	0	100%	1
6JR2_36J_A_301	68%	71%	0.135	0.946	0.58	0.54	-	-	4	0	100%	0.48
5IE4_36J_B_301	22%	28%	0.287	0.904	1.48	1.42	3	6	4	0	100%	1
4TUZ_36J_A_601	83%	16%	0.097	0.954	2.18	1.5	8	7	0	0	100%	1
5XO7_36J_B_301	74%	19%	0.139	0.971	1.74	1.72	6	9	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.